A simple test for growth hormone deficiency in adults.

Mahajan T, Lightman SL

The Journal of clinical endocrinology and metabolism1 Apr 2000Cited by 20 (Europe PMC)

PMID10770184DOI10.1210/jcem.85.4.6545PepBankPUB-10770184

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

01HumanNot a test of GHRP-2 aloneObservational studyActivity measurement
In healthy volunteers and adults with hypopituitarism or GH deficiency, the GHRH plus GHRP‑2 test produced a measurable GH secretory response.
In plain wordsIn healthy adults and in adults with pituitary disease, the GHRH plus GHRP‑2 test produced a measurable GH response.
Peptide
GHRP-2
Outcome
IncreaseGH response to the GHRH/GHRP test
Study
n = 66
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The GHRH/GHRP test produces a measurable GH secretory response in normal, hypopituitary and GH-deficient patients.
1 context sentence(design, population, supporting numbers)
Summary · context
We have compared the GH response to ITT and GHRH/GHRP in a large group of adults with hypothalamic/pituitary disease (n = 36; 22 males and 14 females; age, 18 -59 yr) and in healthy volunteers (n = 30; 15 males and 15 females; age, 22-66 yr).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1077018401
02HumanNot a test of GHRP-2 aloneObservational studySafety outcome
The abstract reports that the GHRH plus GHRP‑2 test had no side effects.
In plain wordsThe report says the GHRH plus GHRP‑2 test had no side effects.
Peptide
GHRP-2
Outcome
No significant changeSide effects of the GHRH/GHRP test
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The test has no side effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We have compared the GH response to ITT and GHRH/GHRP in a large group of adults with hypothalamic/pituitary disease (n = 36; 22 males and 14 females; age, 18 -59 yr) and in healthy volunteers (n = 30; 15 males and 15 females; age, 22-66 yr).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1077018402
03HumanNot a test of GHRP-2 aloneObservational studyOther
With a cut-off of 17 mU/L, the GHRH plus GHRP‑2 test had 78.6% sensitivity for GH deficiency, using the insulin tolerance test as the standard.
In plain wordsAs a test for adult GH deficiency, the GHRH plus GHRP‑2 test found 78.6% of cases that the insulin tolerance test found.
Peptide
GHRP-2
Outcome
Not applicableSensitivity of the GHRH/GHRP test for GH deficiency
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
sensitivity
78.6%
cut-off 17 mU/L
Source sentences
Summary
Choosing an arbitrary cut-off of 17 mU/L to define GHD in the GHRH/GHRP test, this new test proved to have 78.6% sensitivity and 100% specificity even when we only used the 30-min datum point.
2 context sentences(design, population, supporting numbers)
Summary · context
Using the ITT as our 'gold standard' with a GH response of 9 mU/L as our cut-off to define GHD, we compared the clinical efficacy of these two tests.
Summary · context
We have compared the GH response to ITT and GHRH/GHRP in a large group of adults with hypothalamic/pituitary disease (n = 36; 22 males and 14 females; age, 18 -59 yr) and in healthy volunteers (n = 30; 15 males and 15 females; age, 22-66 yr).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1077018403
04HumanNot a test of GHRP-2 aloneObservational studyOther
With a cut-off of 17 mU/L, the GHRH plus GHRP‑2 test had 100% specificity for GH deficiency, using the insulin tolerance test as the standard.
In plain wordsAs a test for adult GH deficiency, the GHRH plus GHRP‑2 test gave no false positives against the insulin tolerance test.
Peptide
GHRP-2
Outcome
Not applicableSpecificity of the GHRH/GHRP test for GH deficiency
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
specificity
100%
cut-off 17 mU/L
Source sentences
Summary
Choosing an arbitrary cut-off of 17 mU/L to define GHD in the GHRH/GHRP test, this new test proved to have 78.6% sensitivity and 100% specificity even when we only used the 30-min datum point.
2 context sentences(design, population, supporting numbers)
Summary · context
Using the ITT as our 'gold standard' with a GH response of 9 mU/L as our cut-off to define GHD, we compared the clinical efficacy of these two tests.
Summary · context
We have compared the GH response to ITT and GHRH/GHRP in a large group of adults with hypothalamic/pituitary disease (n = 36; 22 males and 14 females; age, 18 -59 yr) and in healthy volunteers (n = 30; 15 males and 15 females; age, 22-66 yr).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1077018404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.